How Neuropeptides Drive Severe Itching in Bullous Pemphigoid

Substance P, neurokinin 1 receptor, and IL-31 signaling are key drivers of itch in bullous pemphigoid, offering potential therapeutic targets.

Hashimoto, Takashi et al.·Journal of the American Academy of Dermatology·2020·Preliminary EvidenceObservational (cross-sectional)
RPEP-04844Observational (cross Sectional)Preliminary Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational (cross-sectional)
Evidence
Preliminary Evidence
Sample
N=30
Participants
24 bullous pemphigoid patients and 6 healthy controls

What This Study Found

Itch severity in bullous pemphigoid correlates with eosinophils, substance P, neurokinin 1 receptor, IL-31 signaling, IL-13, periostin, and basophils, while mast cells and TRPV1 were not significantly correlated.

Key Numbers

24 BP patients; 6 controls; itch correlated with SP, NK1R, IL-31RA, eosinophils, IL-13, periostin, basophils

How They Did This

Immunofluorescence staining of skin lesions from 24 BP patients and 6 healthy controls, with correlation analysis between mediator expression and itch severity.

Why This Research Matters

Identifying specific neuropeptide and immune pathways driving itch in BP could lead to targeted therapies like NK1R antagonists or anti-IL-31 drugs, replacing broad immunosuppression.

The Bigger Picture

Understanding neuropeptide-driven itch mechanisms in autoimmune blistering diseases opens the door to targeted anti-itch treatments that could benefit patients with BP and related conditions.

What This Study Doesn't Tell Us

Small sample size (30 total). Cross-sectional design cannot establish causation. Limited to immunofluorescence analysis without functional assays.

Questions This Raises

  • ?Would NK1R antagonists effectively reduce itch in BP patients?
  • ?Do anti-IL-31 therapies like nemolizumab work for BP-associated itch?
  • ?Why are mast cells not correlated with itch severity despite their established role in other pruritic conditions?

Trust & Context

Key Stat:
24 patients BP patients whose skin lesions were analyzed for itch mediator expression
Evidence Grade:
Small observational study providing correlational evidence. Immunofluorescence-only analysis without functional validation limits conclusions.
Study Age:
Published in 2020, the findings remain relevant as targeted anti-itch therapies continue to develop.
Original Title:
Pathophysiologic mechanisms of itch in bullous pemphigoid.
Published In:
Journal of the American Academy of Dermatology, 83(1), 53-62 (2020)
Database ID:
RPEP-04844

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What causes the severe itching in bullous pemphigoid?

This study found that multiple neuropeptide and immune signals drive BP itch, including substance P, neurokinin 1 receptor, IL-31 signaling, and eosinophils. The itch appears to be mediated through both nervous system and immune pathways.

Are there targeted treatments for BP itch?

The findings suggest substance P blockers (NK1R antagonists) and anti-IL-31 therapies could target BP itch specifically, though clinical trials are needed to confirm this.

Read More on RethinkPeptides

Cite This Study

RPEP-04844·https://rethinkpeptides.com/research/RPEP-04844

APA

Hashimoto, Takashi; Kursewicz, Christina Dorothy; Fayne, Rachel Alison; Nanda, Sonali; Shah, Serena Maya; Nattkemper, Leigh; Yokozeki, Hiroo; Yosipovitch, Gil. (2020). Pathophysiologic mechanisms of itch in bullous pemphigoid.. Journal of the American Academy of Dermatology, 83(1), 53-62. https://doi.org/10.1016/j.jaad.2019.07.060

MLA

Hashimoto, Takashi, et al. "Pathophysiologic mechanisms of itch in bullous pemphigoid.." Journal of the American Academy of Dermatology, 2020. https://doi.org/10.1016/j.jaad.2019.07.060

RethinkPeptides

RethinkPeptides Research Database. "Pathophysiologic mechanisms of itch in bullous pemphigoid." RPEP-04844. Retrieved from https://rethinkpeptides.com/research/hashimoto-2020-pathophysiologic-mechanisms-of-itch

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.